Data Sheet (Cat.No.T12171)

TargetMol

Nampt-IN-5

Chemical Properties



CAS No. : 2380013-17-0

Formula: C25H25N5O2

Molecular Weight: 427.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Nampt-IN-5 is a potent and orally active inhibitor of nicotinamide phosphoribosyltransferase (NAMPT).
Targets(IC50)	Cytochromes P450,NAMPT
In vitro	Nampt-IN-5 shows a good ADME data: mouse microsomal clearance, CYP3A4 inhibition value (0.75 μM), Sol6.8: 0.056 mM; MDCK Papp AB: 18.6.Nampt-IN-5 has cellular IC50s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively in CellTiterGlo (CTG) assays[1].

Solubility Information

Solubility	DMSO: 48 mg/mL (112.28 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.68 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3392 mL	11.6959 mL	23.3918 mL
5 mM	0.4678 mL	2.3392 mL	4.6784 mL
10 mM	0.2339 mL	1.1696 mL	2.3392 mL
50 mM	0.0468 mL	0.2339 mL	0.4678 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Palacios DS, et al. Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).ACS Med Chem Lett. 2019 Oct 10;10(11):1524-1529.